Claims for Patent: 11,679,110

Summary for Patent: 11,679,110

Title:	Methods of treating disorders using CSF1R inhibitors
Abstract:	Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Inventor(s):	Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US17/358,137
Patent Claims:	1. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising orally administering to the patient about 2 mg to about 50 mg of a compound represented by the formula: or a pharmaceutically acceptable salt thereof, twice weekly. 2. The method of claim 1, comprising orally administering to the patient about 5 mg to about 30 mg of the compound twice weekly. 3. The method of claim 1, comprising orally administering to the patient about 20 mg of the compound twice weekly. 4. The method of claim 1, comprising orally administering to the patient about 14 mg of the compound twice weekly. 5. The method of claim 1, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 6. The method of claim 1, wherein the tumor is benign. 7. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising orally administering to the patient about 30 mg of a compound represented by the formula: twice weekly. 8. The method of claim 7, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 9. The method of claim 7, wherein the tumor is benign. 10. The method of claim 7, comprising administering to the patient the compound twice weekly for about 6 months. 11. The method of claim 7, comprising administering to the patient the compound twice weekly for about 1 year. 12. A method of treating tumors known to have expression of the receptor colony-stimulating factor 1 receptor (CSF1R) or its ligands, colony stimulating factor-1 (CSF1) or interleukin (IL)-34, in a patient in need thereof, comprising administering to the patient about 2 mg to about 60 mg of a compound represented by the formula: or a pharmaceutically acceptable salt thereof, twice weekly. 13. The method of claim 12, comprising orally administering to the patient about 5 mg to about 30 mg of the compound twice weekly. 14. The method of claim 12, comprising orally administering to the patient about 30 mg of the compound twice weekly. 15. The method of claim 12, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 16. The method of claim 12, wherein the tumor is benign. 17. The method of claim 12, comprising determining if the tumor expresses CSF1R, CSF1, or IL-34 from the patient's extracted tumor sample, or patient's extracellular fluid. 18. The method of claim 12, comprising determining if the tumor's microenvironment expresses CSF1R, CSF1, or IL-34 from the patient's extracted tumor sample, or patient's extracellular fluid.